DEF 14A: Aura Biosciences Seeks Stockholder Approval for Officer Liability Protection and Director Elections at 2024 Annual Meeting

Aura Biosciences is holding its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, to vote on director elections, officer exculpation, and auditor ratification.

Summary

• Aura Biosciences will hold its 2024 Annual Meeting of Stockholders online on June 20, 2024, at 9:30 a.m. Eastern Time.
• Stockholders of record as of April 22, 2024, are eligible to vote.
• The meeting will address the election of two Class III directors, an amendment to the certificate of incorporation regarding officer exculpation, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board of Directors recommends voting for the election of Antony Mattessich and Sapna Srivastava, Ph.D. as Class III directors.
• The Board of Directors recommends voting for the amendment to the certificate of incorporation to limit officer liability.
• The Board of Directors recommends voting for the ratification of Ernst & Young LLP as the independent auditor.
• The company had 49,533,018 shares of common stock outstanding as of April 22, 2024.
• Aura Biosciences is an emerging growth company and is permitted to conform with certain reduced public company reporting requirements.

Sentiment

Score: 7

Explanation: The document is neutral to positive. It outlines standard corporate governance procedures and seeks approval for measures that could benefit the company's ability to attract and retain talent. There are no significant negative indicators.

Positives

• The proposed amendment to the certificate of incorporation aims to attract and retain executive talent by limiting officer liability, aligning with Delaware General Corporation Law.
• The virtual format of the Annual Meeting is designed to enhance stockholder access, participation, and communication.
• The Board of Directors is committed to creating a board of directors with diversity, including diversity of expertise, experience, background and gender.
• The Audit Committee has adopted policies and procedures relating to the approval of all audit and non-audit services that are to be performed by our independent registered public accounting firm.

Negatives

• Raj Parekh, Ph.D. has notified the Company of his intention to resign as a member of the Board of Directors, effective on the date of the Annual Meeting.

Risks

• Failure to approve the amendment to the certificate of incorporation could adversely impact the company's ability to attract and retain highly qualified officer candidates.
• The nature of the role of directors and officers often requires them to make decisions on crucial matters, which can create substantial risk of investigations, claims, actions, suits or proceedings seeking to impose liability on the basis of hindsight, especially in the current litigious environment and regardless of merit.

Future Outlook

The company intends to comply with all applicable requirements of Nasdaq and the rules and regulations of the SEC.

Management Comments

• Our Board of Directors believes that limiting concern about personal liability will empower officers to best exercise their business judgment in furtherance of stockholder interests without the distraction of potentially being subject to claims following actions taken in good faith.
• Our Board of Directors believes it is important to provide protection to officers to the extent permitted by the DGCL to attract and retain executive talent.

Industry Context

The amendment to the certificate of incorporation regarding officer exculpation aligns Aura Biosciences with other public companies updating their governing documents to reflect changes in Delaware General Corporation Law.

Comparison to Industry Standards

• The corporate law codes of several other states already permit corporations to exculpate officers in a similar manner to Section 102(b)(7) of the DGCL.
• Other public companies have updated their governing documents to align with amended Section 102(b)(7) of the DGCL, and we expect this practice to continue.

Corporate Governance

Stakeholder Impact

• Approval of the officer exculpation amendment could benefit stockholders by enabling officers to make decisions in the best interest of the company without undue concern for personal liability.
• The election of directors will shape the leadership and oversight of the company.
• Ratification of the auditor ensures continued independent oversight of the company's financial reporting.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will file a Form 8-K with the SEC to announce the final voting results after the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Director Election, Officer Exculpation, Auditor Ratification, Corporate Governance, Aura Biosciences